Cryptogenic stroke and underlying atrial fibrillation

Author(s): Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, et al.

Abstract

Background:Current guidelines recommend at least 24 hours of electrocardiographic (ECG) monitoring after an ischemic stroke to rule out atrial fibrillation. However, the most effective duration and type of monitoring have not been established, and the cause of ischemic stroke remains uncertain despite a complete diagnostic evaluation in 20 to 40% of cases (cryptogenic stroke). Detection of atrial fibrillation after cryptogenic stroke has therapeutic implications.

Methods:We conducted a randomized, controlled study of 441 patients to assess whether long-term monitoring with an insertable cardiac monitor (ICM) is more effective than conventional follow-up (control) for detecting atrial fibrillation in patients with cryptogenic stroke. Patients 40 years of age or older with no evidence of atrial fibrillation during at least 24 hours of ECG monitoring underwent randomization within 90 days after the index event. The primary end point was the time to first detection of atrial fibrillation (lasting >30 seconds) within 6 months. Among the secondary end points was the time to first detection of atrial fibrillation within 12 months. Data were analyzed according to the intention-to-treat principle.

Results:By 6 months, atrial fibrillation had been detected in 8.9% of patients in the ICM group (19 patients) versus 1.4% of patients in the control group (3 patients) (hazard ratio, 6.4; 95% confidence interval [CI], 1.9 to 21.7; P<0.001). By 12 months, atrial fibrillation had been detected in 12.4% of patients in the ICM group (29 patients) versus 2.0% of patients in the control group (4 patients) (hazard ratio, 7.3; 95% CI, 2.6 to 20.8; P<0.001).

Conclusions:ECG monitoring with an ICM was superior to conventional follow-up for detecting atrial fibrillation after cryptogenic stroke. (Funded by Medtronic; CRYSTAL AF ClinicalTrials.gov number, NCT00924638.).

Similar Articles

Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study

Author(s): Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, et al.

Edoxaban versus warfarin in patients with atrial fibrillation

Author(s): Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, et al.

Dabigatran versus warfarin in patients with atrial fibrillation

Author(s): Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, et al.

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Author(s): Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, et al.

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Author(s): Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, et al.

End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience

Author(s): Mahaffey KW, Hellkamp AS, Patel MR, Hannan KL, Schwabe K, et al.

Apixaban versus warfarin in patients with atrial fibrillation

Author(s): Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, et al.

Apixaban in patients with atrial fibrillation

Author(s): Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, et al.

Edoxaban versus warfarin in patients with atrial fibrillation

Author(s): Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, et al.

Thrombolysis with alteplase 3 to 4

Author(s): Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, et al.